复方苦参注射液联合化疗治疗晚期胃癌安全性和有效性的Meta分析  

Meta analysis of the safety and efficacy of compound kushen injection combined with chemotherapy in the treatment of advanced gastric cancer

作　　者：尚志忠 陶功财 周雅丽[1] 方亚男 潘云燕[3] 杨学敏[3] 任磊 SHANG Zhizhong;TAO Gongcai;ZHOU Yali;FANG Ya’nan;PAN Yunyan;YANG Xuemin;REN Lei(Cuiying Biomedical Research Center,the Second Hospital of Lanzhou University,Lanzhou 730030,Gansu,China;The Second Clinical Medical College of Lanzhou University,Lanzhou 730000,Gansu,China;Clinical Laboratory Center,the Second Hospital of Lanzhou University,Lanzhou 730030,Gansu,China)

机构地区：[1]兰州大学第二医院萃英生物医学研究中心,兰州730030 [2]兰州大学第二临床医学院,兰州7300000 [3]兰州大学第二医院检验医学中心,兰州730030

出　　处：《癌症进展》2020年第21期2200-2204,2219,共6页Oncology Progress

基　　金：兰州大学第二医院萃英学子科研培育计划(CYXZ-33);兰州大学第二医院“萃英科技创新”计划(CY2018-BJ04)。

摘　　要：目的系统评价复方苦参注射液联合化疗治疗晚期胃癌的安全性和有效性。方法通过计算机在PubMed、Cochrane、Ovid-Embase、中国知网、中国生物医学文献数据库、万方数据库中检索相关文献,检索截止时间为2019年11月1日。根据纳入和排除标准,筛选复方苦参注射液联合化疗(试验组)和单纯化疗(对照组)治疗晚期胃癌的文献,由两名研究人员独立提取资料,并对纳入文献进行质量评价,采用RevMan 5.3软件对数据进行Meta分析。结果共纳入17个随机对照试验,包括1416例晚期胃癌患者。Meta分析结果显示,试验组患者的总有效率明显高于对照组,差异有统计学意义(RR=1.32,95%CI:1.18~1.47,P﹤0.01);试验组患者的生存质量改善率明显高于对照组,差异有统计学意义(RR=1.42,95%CI:1.21~1.67,P﹤0.01);试验组患者的白细胞减少发生率明显低于对照组,差异有统计学意义(RR=0.64,95%CI:0.56~0.73,P﹤0.01);试验组患者的血小板减少发生率明显低于对照组,差异有统计学意义(RR=0.54,95%CI:0.45~0.65,P﹤0.01);试验组患者的恶心呕吐发生率明显低于对照组,差异有统计学意义(RR=0.66,95%CI:0.57~0.77,P﹤0.01);但两组患者的肝功能损伤发生率比较,差异无统计学意义(RR=0.60,95%CI:0.33~1.07,P=0.08)。结论相较于单纯化疗,复方苦参注射液联合化疗可显著提高晚期胃癌患者的化疗效果,并降低化疗相关不良反应的发生率。Objective To evaluate the safety and efficacy of compound kushen injection combined with chemotherapy in the treatment of advanced gastric cancer.Method PubMed,Cochrane,Ovid-Embase,CNKI,CBM and WanFang Data were searched by computer until November 1,2019.According to the inclusion and exclusion criteria,the literatures on the treatment of advanced gastric cancer with compound kushen injection combined with chemotherapy(experiment group)and chemotherapy alone(control group)were screened.The data were extracted independently by two researchers,and the quality of the included literatures was evaluated.The data were analyzed by RevMan 5.3 software.Result 17 randomized controlled trials were included,including 1416 patients with advanced gastric cancer.The results of Meta analysis showed that the overall response rate of experiment group was higher than that of the control group(RR=1.32,95%CI:1.18-1.47,P<0.01),the improvement rate of quality of life of experiment group was higher than that of the control group(RR=1.42,95%CI:1.21-1.67,P<0.01),the leukopenia rate of experiment group was lower than that of the control group(RR=0.64,95%CI:0.56-0.73,P<0.01),the thrombocytopenia rate of experiment group was lower than that of the control group(RR=0.54,95%CI:0.45-0.65,P<0.01),the incidence of nausea and vomiting of experiment group was lower than that of the control group(RR=0.66,95%CI:0.57-0.77,P<0.01).However,there was no significant difference in the incidence of liver function injury between the two groups(RR=0.60,95%CI:0.33-1.07,P=0.08).Conclusion Compared with chemotherapy alone,compound kushen injection combined with chemotherapy can significantly improve the chemotherapeutic effect and reduce the incidence of chemotherapy-related side effects in patients with advanced gastric cancer.

关 键 词：复方苦参注射液 化疗 晚期胃癌 安全性 有效性 META分析 

分 类 号：R735.2[医药卫生—肿瘤]